Business Wire

Vor Systems Raises $3M Pre-Seed to Unblock Complex Renewable Energy Transactions

SAN FRANCISCO--(BUSINESS WIRE)--Vor Systems, an AI-enabled transaction platform built for complex renewable energy deals, today announced it has raised $3 million in pre-seed funding led by Gigascale ...
Times Higher Education

Tips for running engaging tutorials

Practical strategies for turning tutorials into active, inclusive learning spaces, from designing hands-on activities and valuing student contributions to building rapport and providing effective ...
The Globe and Mail

Vor Biopharma CDO Departs, Transition Support Planned

Vor Biopharma ( (VOR)) just unveiled an update. On December 31, 2025, Vor Biopharma Inc. entered into a separation agreement with its Chief Development Officer, Dr. Qing Zuraw, following her decision ...
Yahoo Finance

Vor Biopharma (VOR): Valuation Check After Positive Telitacicept Phase 3 Data and Upbeat JPMorgan Coverage

Vor Biopharma (VOR) has jumped onto investors’ radar after strong Phase 3 data for telitacicept in IgA nephropathy, paired with upbeat new Wall Street coverage that frames the drug’s long term ...
Hosted on MSN

Vor Biopharma approves stock option repricing plan

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
Seeking Alpha

Vor Bio spikes as J.P. Morgan starts at Overweight on lead asset

Vor Biopharma (VOR) rose ~17% on Tuesday after J.P. Morgan initiated its coverage with an Overweight recommendation and a Dec. 2026 price target of $43, citing a potential blockbuster status for the ...
Investing

JPMorgan initiates Vor Biopharma stock with Overweight rating, $43 target

Investing.com - JPMorgan has initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with an Overweight rating and a price target of $43.00, highlighting the potential of the company’s telitacicept ...
Investing

JPMorgan initiates Vor Biopharma stock with Overweight rating on telitacicept potential

Investing.com - JPMorgan initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with an Overweight rating and a $43.00 price target, citing the potential of its telitacicept drug. The target ...
Nasdaq

Vor Biopharma (VOR) Upgraded to Buy: Here's What You Should Know

Vor Biopharma Inc. (VOR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...
Business Insider

Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock

BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR) (Vor Bio), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today ...
Seeking Alpha

Vor Biopharma upgraded to Buy at Stifel on telitacicept prospects

Vor Biopharma (NASDAQ:VOR) has been upgraded to Buy from Hold at Stifel as confidence in the company’s long-term potential has grown following prospects for its lead asset, telitacicept. The shares of ...